Servier

About Servier
Servier is an international independent pharmaceutical group headquartered in France. The group is managed by a not-for-profit foundation, which allows it to pursue, based on a long-term vision, the company's mission - to contribute to therapeutic progress to meet patient needs and take their interests into account at every stage of the drug life cycle.
A leader in the treatment of cardiology and chronic venous diseases1, Servier aims to take a leading position in the field of innovation in oncology and neurology...

About Servier
Servier is an international independent pharmaceutical group headquartered in France. The group is managed by a not-for-profit foundation, which allows it to pursue, based on a long-term vision, the company's mission - to contribute to therapeutic progress to meet patient needs and take their interests into account at every stage of the drug life cycle.
A leader in the treatment of cardiology and chronic venous diseases1, Servier aims to take a leading position in the field of innovation in oncology and neurology. Based on the principles of personalized medicine, the Group develops targeted therapy drugs for the treatment of rare diseases, investing about 20% of the turnover of original drugs in research and development.
Servier operates in more than 130 countries worldwide. The total number of employees is over 20,000 people. In the 2024/25 financial year, the company's annual turnover amounted to 6.9 billion Euro.
Servier has been operating in Russia for almost 35 years, being one of the leading pharmaceutical companies. In 2007, the high-tech production complex Servier RUS was launched in New Moscow. It operates in full compliance with the requirements of the international standard of Good Manufacturing Practice (GMP) and produces a wide range of modern original drugs for the treatment of major chronic diseases for patients in Russia and other countries of the Eurasian Economic Union. Today, more than 90% of original Servier drugs in Russia are manufactured at a pharmaceutical plant in Moscow on a full-cycle basis.

Additional information: www.servier.ru

Social networks:
Telegram https://t.me/ServierRussia
VK https://vk.com/servier_russia
Yandex.Zen https://zen.yandex.ru/id/6230ace82d4ef7371fcfb5eb
Odnoklassniki https://ok.ru/servier.russia
Rutube https://rutube.ru/u/servierrussia/
__________________________________________
1IQVIA Research, Link to Analytical Data / 84 Countries / 2025 – IQVIA Research based on the commercial market analytics database IQVIA Analytics Link in 84 countries, including Russia, which aggregates data on the purchase and sales of drugs presented on the markets of these countries. The data is grouped according to standard industry classifiers, including by therapeutic groups - drugs for the treatment of cardiovascular diseases, venous diseases. The study period is October 2024 – September 2025.